Civatech Oncology, founded in Durham, United States, is dedicated to advancing cancer treatment through the development of polymer-based medical devices that deliver localized low-dose-rate radiation. The company's core mission is to provide precision therapy without the need for traditional radiation beams, thereby improving patient outcomes and reducing side effects. Their product lineup includes CivaSheet®, CivaString®, and CivaDerm™, which are designed for various cancer types such as colorectal, gynecological, pancreatic, head and neck, lung, and sarcoma.

Civatech Oncology has garnered attention from notable investors and medical professionals who support its innovative approach to cancer treatment. The company’s key achievements include the successful implementation of their products in clinical settings, significantly enhancing the efficacy of brachytherapy. The impact of Civatech Oncology's technology is evident in improved patient survival rates and quality of life, positioning the company as a leader in the field of localized radiation therapy.